Project Grant R44AG079691
- This Project Grant award from the National Institutes of Health's Aging Research program (CFDA 93.866) will support research to identify early transcriptional and pathological changes in brain regions vulnerable to Alzheimer's disease (AD). The $459,076 award, granted to Trustees of Boston University, will use single-nucleus RNA sequencing and targeted mass spectrometry to profile cell type-specific gene expression and tau/amyloid beta proteoforms in the transentorhinal cortex, entorhinal...
- This Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), provides $4,041,438 to develop new computational tools and biomarkers for Alzheimer's disease. The University of Miami will aggregate and analyze DNA methylation datasets to identify age-associated epigenetic changes related to aging and Alzheimer's progression. Researchers will create a searchable web interface to disseminate findings on the role of DNA...
- This Project Grant award of $423,994 from the National Institute on Aging (CFDA 93.866 - Aging Research) to Duke University aims to characterize spatial variations in RNA isoform expression in relation to Alzheimer's disease (AD) pathology. The research will leverage single-nucleus cDNA, long-read RNA sequencing, and in situ sequencing to profile isoform expression at single-cell resolution in the inferior frontal gyrus, a brain region pertinent to AD. The study will identify cell-type...
- Project Grant Summary: Neuroimaging-Genomic Fingerprints for Alzheimer's Disease Subtyping Wake Forest University Health Sciences received a $770,558 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective July 1, 2025, through March 31, 2030. The grant supports research to establish connections between Alzheimer's disease (AD)-related genomic markers and neuroimaging phenotypes to identify disease subtypes and predict clinical...
- Federal Project Grant Award Summary Duke University's Office of Research Administration is conducting a five-year research project funded by the National Institute on Aging under the Aging Research program (CFDA 93.866), with $493,972 obligated for the project period spanning January 1, 2026, through December 31, 2030. The project, titled "Cell Type-Specific Epitranscriptomic Regulation in the Brain in Aging and Alzheimer's Disease," focuses on understanding how adenosine methylation...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded $454,937 to Stony Brook University under the Aging Research program (CFDA 93.866) on February 15, 2026, for a project period extending through January 31, 2028. The grant funds research investigating the regulatory landscape of neurodegeneration in Alzheimer's disease (AD) through single-cell spatial multiomics analysis. The project addresses a critical gap in understanding how cells in proximity to AD...
- This Project Grant award of $328,000 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the Alzheimer's Disease Organelle Proteome Task (ADOPT) pilot phase. The interdisciplinary research team, led by Drs. Biao Wang and Danielle Swaney at the University of California, San Francisco, will use a genetic organelle tagging approach to rapidly purify lysosomes from neurons in wild-type and Alzheimer's disease mouse models. A suite of mass spectrometry experiments will then...
- This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
- Award Summary The National Institute on Aging awarded Brigham and Women's Hospital a $7.42 million Cooperative Agreement under the Aging Research program (CFDA 93.866) effective July 1, 2025, through June 30, 2030, to develop the Precision-AD Center. This initiative will establish a toolkit of two-dimensional and three-dimensional microphysiological systems (MPS) designed to model Alzheimer's disease and related dementias across genetically diverse populations. The project leverages induced...
- This Project Grant award, provided by the National Institute on Aging under CFDA Program 93.866 - Aging Research, supports a $2,516,316 research initiative led by Harvard Medical School to investigate neuronal activity-responsive DNA repair mechanisms and their contribution to cognitive aging and Alzheimer's disease. The key products and services to be delivered under this 3-year grant include: Mapping the landscape of activity-induced DNA double-strand breaks (DSBs) in wild-type mice and...
SINGLE-CELL EPIGENOME ANALYSIS OF THE ALZHEIMER'S DISEASE BRAIN - PROJECT SUMMARY LATE ONSET AD (LOAD) IS A HETEROGENEOUS DISEASE THAT INVOLVES COMPLEX INTERACTIONS BETWEEN GENETIC, EPIGENETIC, AND ENVIRONMENTAL RISK FACTORS. GENOME-WIDE ASSOCIATION STUDIES (GWAS) HAVE IDENTIFIED SEVERAL THOUSAND SEQUENCE VARIANTS LINKED TO INCREASED OR DECREASED RISK OF AD, MOST OF WHICH ARE NONCODING. THE CURRENT PARADIGM POSITS THAT NONCODING VARIANTS CONTRIBUTE TO DISEASE ETIOLOGY BY PERTURBING TRANSCRIPTIONAL REGULATION IN DISEASE-RELEVANT CELL TYPES, WHILE ENVIRONMENTAL RISK FACTORS CONTRIBUTE TO PATHOGENESIS IN PART VIA ALTERATIONS TO THE EPIGENOME. HOWEVER, A LACK OF MAPS AND TOOLS TO EXPLORE GENE ACTIVITIES AND THEIR TRANSCRIPTIONAL REGULATION AT CELLULAR RESOLUTION IN THE BRAIN HAS PRESENTED A MAJOR BOTTLENECK TO THE FUNCTIONAL INTERPRETATION OF NONCODING AD RISK VARIANTS. IN PRIOR WORK, WE APPLIED DROPLET PAIRED-TAG MULTI-OMIC PROFILING OF TRANSCRIPTION AND HISTONE POST-TRANSLATIONAL MODIFICATION TO POST-MORTEM AD AND CONTROL PARIETAL CORTEX, DEMONSTRATING ITS CAPACITY TO PROFILE CELLULAR EPIGENETICS AND TRANSCRIPTION FROM BULK SAMPLES. THIS TECHNOLOGY HAS GARNERED SIGNIFICANT INTEREST THROUGH OUR EARLY-ACCESS PROGRAM. IN THE PROPOSED STUDY, WE WILL DEVELOP A MANUFACTURING QUALITY MANAGEMENT SYSTEM INCORPORATING REFERENCES AND REFERENCE MEASUREMENTS FOR THE PRODUCTION OF DROPLET PAIRED-TAG KITS. WE WILL OPTIMIZE OUR PROTOCOLS SPECIFICALLY ON POST-MORTEM AD AND HEALTHY BRAIN TISSUE FROM HIPPOCAMPUS, WHITE MATTER, AND CEREBELLUM, AS WELL AS ON PERIPHERAL BLOOD; AND FURTHER OPTIMIZE DROPLET PAIRED-TAG FOR APPLICATION TO SORTED NUCLEAR POPULATIONS. WE WILL PUBLISH THE RESULTING DATA AS A COMPREHENSIVE CELLULAR ENCYCLOPEDIA OF DNA ELEMENTS. IF SUCCESSFUL, THE RESEARCH WOULD CATALYZE THE STUDY OF THE EPIGENETICS OF AD, AND ENABLE THE WIDESPREAD APPLICATION OF NEXT-GENERATION MULTI-OMIC ASSAYS TO AD AND OTHER NEUROLOGICAL DISEASES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $964.8k | 8/11/25 | ||
| Not listed | $995.1k | 9/18/24 |